Statistical considerations in conducting clinical trial

Important Elements in a Clinical Trial Protocol

Trial for viral hepatitis

Trial for liver cancer

Novel molecular targets in HCC

Novel molecular targets for anti-angiogenesis treatment for HCC

Searching for novel therapeutic targets for HCC

Current clinical status of targeted therapies for HCC

The optimal therapeutic strategy of chronic hepatitis B
Gui-Qiang Wang (王贵强), Beijing

The role of JGH in promoting Hepatology in Asia: from the Editor in Chief
Geoffrey C. Farrell, Canberra

Be a clinical or academic hepatologist?
Ji-Dong Jia (贾继东), Beijing

Challenges to endoscopic management of upper GI bleeding in chronic liver disease
Ambrose C.P. Kwan (关治邦), Hong Kong

Signaling pathways in HBV and HCV related HCC
Jack R. Wands, Providence

Diagnosis of Wilson's disease in the Post-genomic Era
Eric C.W. Lam (林青云), Hong Kong

 

General: adjuvant therapy for liver cancer, with special report of 131I treatment
Joseph W.Y. Lau (刘允怡), Hong Kong

IFN adjuvant therapy for liver cancer
Hui-Chuan Sun (孙惠川), Shanghai

IFN+5FU adjuvant therapy for liver cancer
Hiroaki Nagano, Osaka

5FU based adjuvant for hepatocellular carcinoma: a randomized trial
Kiyoshi Hasegawa, Tokyo

Technical aspects of the anatomical liver resection procedure
Mitsuo Shimada, Tokushima

Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma
Ning Li (李宁), Beijing

New trends on studies of hepatocellular carcinoma

The known and unknown roles played by HBV in HCC

 

Liver transplantation - Changing practice
Roger S. Williams, London

Donor evaluation in living donor liver transplantation
Shu-Sen Zheng (郑树森), Hangzhou

The outcome of 948 cases of liver transplantation for hepatocellular carcinoma: Multi-center experience in Shanghai, China
Jia Fan (樊嘉), Shanghai

Living-related liver transplantation for Wilson's disease
Xue-Hao Wang (王学浩), Nanjing

Adult-to-adult living donor liver transplantation: surgical techniques and innovation
Lv-Nan Yan (严律南), Chengdu

Current status of immunosuppression in liver transplantation
John J. Fung, Cleveland

 

Vaccines against hepatitis B and A - Current status and future prospects
Daniel Shouval, Jerusalem

Prediction hepatocellular carcinoma development in patients with chronic B viral liver diseases by ultrasonography
Hong Ding (丁红), Shanghai

Hepatitis B vaccination: Are boosters necessary?
Richard Y.C. Guan, Singapore

HBsAg seroconversion: the ultimate goal in hepatitis B treatment
Michael P. Manns, Hannover

Hepatitis E infection: east meets west
Tai-Nin Chau (周泰年), Hong Kong

Occult HBV
Jian Sun (孙剑), Guangzhou

 

Molecular mechanism of HCC carcinogenesis
Yang-Chao Chen (陈杨超), Hong Kong

Molecular pathology and genetic alterations of liver cancer
Irene O.L. Ng (吴吕爱莲), Hong Kong

Functional study of EZH2 gene in hepatocellular carcinoma
Hsiang-Fu Kung (孔祥复), Hong Kong

Inflammation and liver cancer: Interweaving of the hepatitis virus, microRNA, aflatoxin B1 and p53 Pathways
Curtis C. Harris, Bethesda

Superior anti-tumor immunity against hepatocellular carcinoma evoked by dendritic cells devoid of interleukin-10
Fang-Ping Huang (黄方平), London

TBC
Qing-Hai Ye (叶青海), Shanghai

 

Non-invasive assessment of liver fibrosis in China
Ji-Dong Jia (贾继东), Beijing

Screening liver fibrosis: la révolution Française
Thierry Poynard, Paris

Updates on transient elastography for HBV patients in China
Jin-Lin Hou (侯金林), Guangzhou

New diagnostic method for liver fibrosis and cirrhosis
KH Han

Review and prospect of non-invasive assessment of liver fibrosis
Nezam H. Afdhal, Dallas

Discussion

 

Functional studies of HBV subgenotypes/mutations associated with the increased risk of HCC
Ming-Liang He (何明亮), Hong Kong

Treatment of hepatitis B infection in the prevention of HCC
Joseph J.Y. Sung (沈袓尧), Hong Kong

 

The impact of hepatitis B e antigen on tumor recurrence and patients survival after curative resection of HCC
Hui-Chuan Sun (孙惠川), Shanghai

 

Introduction of antiviral drug resistance
Stephen A. Locarnini, North Melbourne

Molecular pathogenesis of antiviral resistance in CHB
Daryl T.Y. Lau, Boston

Treatment of HBV drug resistance
Maria Buti-Ferret, Barcelona

Evolution of hepatitis B virus quasispecies and anti-viral resistance
Xin-Xin Zhang (张欣欣), Shanghai

 

 

The Hong Kong experience in treatment for patients with liver failure
Alexander Chiu (邱家骏), Hong Kong

Outstanding dendritic cell perturbation actively participates in pathogenesis of end-stage acute-on-chronic hepatitis B liver failure
Fu-Sheng Wang (王褔生), Beijing

MELD, serum sodium and renal function in end stage liver disease
W. Ray Kim, Rochester

Therapies for acute liver failure
Yu-Ming Wang (王宇明), Chongqing

The etiology and outcome of fulminant liver failure in Korean
Dong-Jin Suh, Seoul

Options of liver transplantation for patients with acute liver failure
Seng-Gee Lim, Singapore

 

Opening Remarks

Embryonic liver developmet

Hepatic stem cells and cancer

Probing the genetic and biology of liver carcinoma fusing moue models and RNA interfa

Beta-catenin signalling in HCC

Regulation of hepatic cancer stem cells

Tumor stem cell in HCC

 

Envelop Antigen Status is Associated with HBV-Specific T-Cell Response and Liver Damage in Patients with Chronic Hepatitis B

Characterization of Circulating CD4+CD25+ Regulatory T Cells in Different Stages of HBV Infected Patients

The hepatitis B small surface antigen induces extracellular secretion of Cyclophilin A: experimental studies and clinical implications

Chemical Genetic Screening of Small-Molecule Inhibitors of Hepatitis B Virus Replication

Management of Chronic Hepatitis B (CHB) Antiviral Resistance – The Asia Experience

Reduced Expression of Toll-Like Receptor 2 on Peripheral Monocytes in chronic HBeAg positive patients

Clevudine Is Highly Effective in HBV DNA Suppression in HBe Antigen-Negative Chronic Hepatitis B

Detection of Angtigen-specific cytotoxic lymphocytes and their association with clinical status in patients with hepatitis B

Retinoic acid-inducible gene I Expression and Function of Monocyte-derived Dendritic Cells in Patients with Hepatitis B virus infection

Preclinical & clinical Development of an Anti-HBV RNAi-Based Therapeutic

Long-Term Follow-Up of Entecavir Treated Protocol-Defined Non-Responders in Rollover Study ETV-901

Three-Year Continuous Entecavir Treatment in Chinese Patients who had Previously Failed Lamivudine: Results from Studies ETV-056 and -050

Personalized Medicine: which Chronic Hepatitis B patients should treat with interferon?

Baseline Characteristics and Early Response Predictors of Therapeutic Outcomes in Telbivudine- or Lamivudine-Treated HBeAg-Positive Chronic Hepatitis B Patients

Entecavir (ETV) Results in Higher HBV DNA Reduction versus Adefovir (ADV) in Antiviral-Naive HBeAg(+) Adults with High HBV DNA: 96 Week Results (E.A.R.L.Y. Study)

Entecavir at Five Years Shows Long-Term Maintenance of High Genetic Barrier to Hepatitis B Virus Resistance

Baseline Parameters and Early Response Predict Therapeutic Outcomes in HBeAg-Negative Chronic Hepatitis B Patients Treated With Telbivudine or Lamivudine

Imaging diagnosis of liver cancer: recent progress
Byun-Ihn Choi, Seoul

Diagnosis and treatment of HCC in Japan: Experience at Chiba and Tokyo University
Masao Omata, Tokyo

Prediction of metastatic recurrence of human hepatocellular carcinoma
Lun-Xiu Qin (钦伦秀), Shanghai

Basic and Translational Epigenetics(-omics) of liver cancer: from the DNA methylation perspective
Jing-De Zhu (朱景德), Shanghai

Biomarkers for prognosis of liver cancer
Siu-Tim Cheung (张兆恬), Hong Kong

PET/CT in the detection of metastatic HCC disease
Chi-Lai Ho (何志礼), Hong Kong

 

Natural history of hepatitis C
Rafael M. Esteban, Barcelona

Hepatitis C and metabolic factors
Geoffrey C. Farrell, Canberra

 

TBC
Bao-En Wang (王宝恩), Beijing

Cirrhotic Portal Hypertension: New Treatment strategies
Shiv Kumar Sarin, New Delhi

Molecular bases of liver fibrosis
Alex Y. Hui (许睿), Hong Kong

Treatment of hepatic fibrosis by traditional chinese medicine
Lie-Ming Xu (徐列明), Shanghai

Anti-hepatic fibrosis and ameliorate introhepatic microcirculatory disorder with TCM
 Jing-Min Zhao (赵景民), Beijing

Assessment of liver fibrosis, what should be used for clinical practice
Anuchit Chutaputti, Bangkok

 

Pathogenesis of hepatic fibrosis

 

The Challenge of HIV & Viral Hepatitis Co-infection

 

Management of acute liver failure – Biological and nonbiological liver support methods
Robert G. Gish, San Francisco

Liver support system - China chapter
Zhong-Ping Duan, Beijing

Liver Support devices - Technological developments, unanswered questions
Roger S. Williams, London

Q&A and Free Discussion – Current, future and alternatives

Adjuvant therapy after resection of hepatocellular carcinoma
Joseph W.Y. Lau (刘允怡), Hong Kong

Apoptosis induction - a novel therapy for hepatocellular carcinoma
Paul B.S. Lai (赖宝山), Hong Kong

Perspective in developing molecular targeted therapy for hepatocellular carcinoma in Asia
Andrew A.L. Cheng (郑安理), Taipei

Novel hepatoprotective strategies against liver ischaemia reperfusion injury
Narci Teoh, Canberra

Silibinin and chemoprevention of hepatocellular carcinoma
Ke-Qin Hu (胡克勤), Orange

How to manage advanced hepatocellular carcinoma
Kwang-Hyub Han, Seoul

 

Current and future management of chronic hepatitis C

Individualizing antiviral treatment duration in chronic hepatitis C

Management of chronic hepatitis C in patients with ESRD

Emerging therapies for hepatitis C

Hepatitis C treatment non-responder - what to do

Management of HCV, HBV in HIV- infected patients

 

Role of genetic in determining diseases outcome of HBV

 

TBC
Meng-Chao Wu (吴孟超), Shanghai

Partial hepatectomy or liver transplantation for patients with hepatocelluar carcinoma fulfilling Milan Criteria
Jian Zhou (周俭), Shanghai

Surgical treatment for recurrence and metastasis of hepatocellular carcinoma
Xiao-Ping Chen (陈孝平), Wuhan

Anti-recurrence studies of hepatocellular carcinoma
Feng Shen (沈锋), Shanghai

Abdominal drainage in hepatobiliary and pancreatic surgery
Chi-Leung Liu (廖子良), Hong Kong

How to extend the indication of liver surgery in colorectal liver metastases
Henri Bismuth, Paris

Hepatitis C in China
Lai Wei (魏来), Beijing

Small molecules in the future therapy of hepatitis C - chances and challenges
Michael P. Manns, Hannover

Nucleic acid testing: role in HBV and HCV management
Robert G. Gish, San Francisco

Prediction for treatment response in chronic hepatitis C
Wan-Cheng Chow (周蕴菁). Singapore

Treatment of HBV & HCV and prevention of HCC development
Masao Omata, Tokyo

Hepatitis C vaccine development
T. Jake Liang, Bethesda

Classification of hepatitis B virus genotypes
Masashi Mizokami, Nagoya

Significance of HBeAg seroconversion in patients with genotpye B and C
James Y.Y. Fung (冯恩裕), Hong Kong

The clinical role of HBV genotypes and subgenotypes
Jia-Horng Kao (高嘉宏), Taipei

Risk of hepatocellular carcinoma associated with genotypes and mutants of hepatitis B virus
Chien-Jen Chen (陈建仁), Taipei

HBV genotype C and HCC: Other predictors of HCC development
Osamu Yokosuka, Chiba

Treatment a la carte for genotype 1
Maria Buti, Barcelona

Technical aspects of the anatomical liver resection procedure
Lu Wang (王鲁), Shanghai

Systemic therapy for hepatocellular carcinoma
Winnie Yeo (杨明明), Hong Kong

Comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma
Min-Shan Chen (陈敏山), Guangzhou

Radiation therapy for primary liver cancer
Zhao-Chong Zeng (曾昭冲), Shanghai

Current role of radiofrequency ablation for HCC
Ronnie T.P. Poon (潘冬平), Hong Kong

Resection vs. invasive RF ablation for hepatocellular cancer
Steven A. Curley, Houston

baseline predictors of HBeAg seroconversion
Seng-See Lim, Singapore

Implication for therapy from the natural history of chronic hepatitis B
W. Graham Cooksley, Brisbane

The roles of interferons and nucleos(t)ide analogue in the therapy of chronic hepatitis B
Jean-Michel Pawlotsky, Paris

treatment options and HBV resistance monitor for hepatitis B in China
Jin-Lin Hou (侯金林), Guangzhou

Combination therapy of CHB - viral suppression and antiviral resistance
Dong- Jin Suh, Seoul

Life long therapy of chronic hepatitis B - indication and sustainability
Nancy W.Y. Leung (梁慧仪), Hong Kong

Systems biology of liver cancer: clues to new therapeutic targets
John M.C. Luk (陆满清), Hong Kong

Dynamic comparative proteomics on discovery of the potential biomarkers during hepatocarcinogenesis and liver cancer metastasis
Yin-Kun Liu (刘银坤), Shanghai

Proteomics approach to study the effects of over-expression of sumo in liver cancer cells
Mary M.Y. Waye (韦妙宜), Hong Kong

Proteomic identification of nucleoprotein(s) that regulate alpha-fetoprotein gene expression in retionic acid-induced F9 cells
Jen-Fu Chiu (邱政夫), Hong Kong

Understanding the clinical outcomes among HCC patients from genomic data
Terence C.W. Poon (潘全威), Hong Kong

Protein phosphorylation and oncogenic signaling
Hong-Yang Wang (王红阳), Shanghai

Current status of live donor liver transplantation

 

Cholangiocarcinoma : A surgeon's perspective
Edward C.S. Lai (黎卓先), Hong Kong

Clinical Trial of HCC: adjuvant Therapies for Post-operative HCC
Pei-Jer Chen (陈培哲), Taipei

Cost-effectiveness of HCC surveillance
Jose D. Sollano, Manila

The impact of acute phase injury on late phase tumor recurrence and metastases

Occult hepatitis B: Infection or detection
F. Blaine Hollinger, Houston

Definition and significance of normal and abnormal serum ALT
W. Ray Kim, Rochester

The role of pathogen-assiociated molecular patterns (PAMPs) in the persistent infection of hepatitis B virus
Guang-Feng Shi (施光峰), Shanghai

Evolving CHB treatment paradigm in Asia, long term vs. short term
Masao Omata, Tokyo

Large deletions in the HBV core gene in inactive, HBeAg- negative chronic HBV infection
Abbott William, Auckland

Risk predictors for progression of chronic hepatitis B: a long-term follow-up study
Chien-Jen Chen (陈建仁), Taipei

 

Opening Remarks
Vivian C.W. Taam Wong, Hong Kong

Comparison of the "liver system" between Chinese Medicine "Gan" and Western Medicine "Liver"
Yao Tong (童瑶), Hong Kong

Safety of using TCM and hepatoxicity
Zhong-Zhen Zhao (赵中振), Hong Kong

Clinic practice and mechanisms of treating liver fibrosis with traditional Chinese medicine
Cheng-Hai Liu (刘成海), Shanghai

 Panal Discussion

Why NASH occurs: 2008 update!
Geoffrey C. Farrell, Canberra

Fatty liver in China: a common and weighty problem
Jian-Gao Fan (范建高), Shanghai

Insulin resistance in chronic hepatitic C
Laurentius A. Lesmana, Jakarta

Management of NAFLD in 2008
Chee-Kin Hui (许志坚), Hong Kong

NASH
Wan-Cheng Chow (周蕴菁). Singapore

Discussion

Immunopathogensis of liver diseases: introduction and the role of T cell
Nikolai V. Naoumov, London

Impaired adaptive immunity against chronic HBV infection and relative mechanisms
Fu-Sheng Wang (王褔生), Beijjing

Immunotherapy for viral hepatitis B: Can we go further?
Yu-Mei Wen (闻玉梅), Shanghai

Severe hepatitis, FHF and ACLF: The role of immune status
Qin Ning (宁琴), Shanghai

Inflammation, cytokines and hepatocellular carcinoma
Xin-Wei Wang (王心伟), Bethesda

The adaptive immunologic microenvironment in hepatocellular carcinoma: a clinical perspective learn from basic research
Shuang-Jian Qiu (邱双健), Shanghai

Molecular classification of liver cancer: is it feasible yet?
Snorri S. Thorgeirsson, Bethesda

Pathology diagnosis of dysplastic nodule and early HCC - New pathology criteria and molecular signatures
Young-Nyui Park, Seoul

The emergence of molecular targeted therapies: the case for sorafenib
Jordi Bruix, Barcelona

Prevention recurrence after resection / ablation: Entering a new era
Ronnie T.P. Poon (潘冬平), Hong Kong

Panel Discussion

Economic aspect of the treatment of chronic hepatitis B
Guang-Bi Yao (姚光弼), Shanghai

Review of guidelines and consensus for the management of chronic hepatitis B
Nancy W.Y. Leung (梁慧仪), Hong Kong

Clinical and histological findings in chronic hepatitis B patients with persistently normal ALT
Qing Xie (谢青), Shanghai

Current and future treatment of CHB
George K.K. Lau (廖家杰), Hong Kong

HBV clinical development: In the view of virologist
 Stephen A. Locarnini, North Melbourne

Road map to long term treatment success
Robert G. Gish, San Francisco